Incyte Corporation (INCY) - Total Liabilities
Based on the latest financial reports, Incyte Corporation (INCY) has total liabilities worth $1.53 Billion USD as of June 2026. Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities. Explore how much of Incyte Corporation's assets are long-term investments to see how much of total assets are deployed in long-term investments.
Incyte Corporation - Total Liabilities Trend (1993–2025)
This chart illustrates how Incyte Corporation's total liabilities have evolved over time, based on quarterly financial data. For the complete balance sheet picture, see INCY total assets.
Incyte Corporation Competitors by Total Liabilities
The table below lists competitors of Incyte Corporation ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
Baidu Inc
MX:BIDUN
|
Mexico | MX$159.43 Billion |
|
HEXAGON AB ADR/1
F:HXGC
|
Germany | €4.68 Billion |
|
Telefónica S.A
MX:TEFN
|
Mexico | MX$71.22 Billion |
|
Guangdong Dtech Technology Co. Ltd. A
SHE:301377
|
China | CN¥2.43 Billion |
|
Zoom Video Communications Inc
NASDAQ:ZM
|
USA | $2.10 Billion |
|
Dassault Aviation SA
PA:AM
|
France | €27.62 Billion |
|
Principal Financial Group Inc
NASDAQ:PFG
|
USA | $339.86 Billion |
|
Alfa Laval AB
ST:ALFA
|
Sweden | Skr58.89 Billion |
Liability Composition Analysis (1993–2025)
This chart breaks down Incyte Corporation's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted. See Incyte Corporation (INCY) net asset quality to measure how much of total assets are equity-financed.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 4.66 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.24 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.19 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Incyte Corporation's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Incyte Corporation (1993–2025)
The table below shows the annual total liabilities of Incyte Corporation from 1993 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-12-31 | $1.80 Billion | -9.68% |
| 2024-12-31 | $2.00 Billion | +25.40% |
| 2023-12-31 | $1.59 Billion | +8.25% |
| 2022-12-31 | $1.47 Billion | +26.43% |
| 2021-12-31 | $1.16 Billion | +22.50% |
| 2020-12-31 | $949.65 Million | +14.64% |
| 2019-12-31 | $828.34 Million | +15.08% |
| 2018-12-31 | $719.79 Million | +7.12% |
| 2017-12-31 | $671.95 Million | -44.88% |
| 2016-12-31 | $1.22 Billion | +45.78% |
| 2015-12-31 | $836.28 Million | -4.76% |
| 2014-12-31 | $878.11 Million | +6.74% |
| 2013-12-31 | $822.68 Million | +62.78% |
| 2012-12-31 | $505.38 Million | -9.11% |
| 2011-12-31 | $556.04 Million | -3.84% |
| 2010-12-31 | $578.23 Million | -29.03% |
| 2009-12-31 | $814.77 Million | +79.81% |
| 2008-12-31 | $453.14 Million | +4.12% |
| 2007-12-31 | $435.21 Million | -0.75% |
| 2006-12-31 | $438.51 Million | +11.44% |
| 2005-12-31 | $393.50 Million | -10.24% |
| 2004-12-31 | $438.40 Million | +94.66% |
| 2003-12-31 | $225.21 Million | -9.82% |
| 2002-12-31 | $249.73 Million | -5.89% |
| 2001-12-31 | $265.36 Million | +0.47% |
| 2000-12-31 | $264.13 Million | +411.87% |
| 1999-12-31 | $51.60 Million | +1.78% |
| 1998-12-31 | $50.70 Million | -5.06% |
| 1997-12-31 | $53.40 Million | +146.08% |
| 1996-12-31 | $21.70 Million | +97.27% |
| 1995-12-31 | $11.00 Million | +134.04% |
| 1994-12-31 | $4.70 Million | +213.33% |
| 1993-12-31 | $1.50 Million | -- |
About Incyte Corporation
Incyte Corporation, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapeutics in the United States, Europe, Canada, and Japan. The company offers JAKAFI for the treatment of myelofibrosis (MF), polycythemia vera, and steroid-refractory acute graft-versus-host disease; ICLUSIG, a kinase inhibitor to treat chronic myeloid leukemia and Philadelphia-chr… Read more